Vaccines for Tuberculosis: Novel Concepts and Recent Progress
Open Access
- 1 October 2005
- journal article
- review article
- Published by American Society for Microbiology in Clinical Microbiology Reviews
- Vol. 18 (4), 687-702
- https://doi.org/10.1128/cmr.18.4.687-702.2005
Abstract
SUMMARY: Three-quarters of a century after the introduction ofMycobacterium bovisBCG, the first tuberculosis vaccine, new vaccines for tuberculosis are finally entering clinical trials. This breakthrough is based not only on advances in proteomics and genomics which have made the construction of new vaccines possible, but also on a greatly expanded knowledge of the immunology of tuberculosis. Here we review our current understanding of howMycobacterium tuberculosissubverts or survives the host's immune response to cause disease and why the current vaccination strategy, which relies on BCG, is only partially successful in countering the pathogen. This provides a background for describing the new generation of vaccines designed to supplement or replace the current vaccine and the different approaches they take to stimulate immunity againstM. tuberculosis.Keywords
This publication has 150 references indexed in Scilit:
- Mycobacterium's Arrest of Phagosome Maturation in Macrophages Requires Rab5 Activity and Accessibility to IronMolecular Biology of the Cell, 2003
- Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrestProceedings of the National Academy of Sciences of the United States of America, 2003
- Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosisNature Medicine, 2003
- Apoptosis Modulation by Mycolic Acid, Tuberculostearic Acid and Trehalose 6,6′-DimycolateJournal of Infection, 2002
- Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequenceNature, 1998
- Severe Mycobacterial and Salmonella Infections in Interleukin-12 Receptor-Deficient PatientsScience, 1998
- Direct presentation of non-peptide prenyl pyrophosphate antigens to human γδ T cellsResearch in Immunology, 1996
- Contribution of α/β and γ/δ T lymphocytes to immunity against Mycobacterium bovis Bacillus Calmette Guérin: studies with T cell receptor‐deficient mutant miceEuropean Journal of Immunology, 1995
- Immune response to Mycobacterium bovis bacille Calmette Guérin infection in major histocompatibility complex class I‐ and II‐deficient knock‐out mice: contribution of CD4 and CD8 T cells to acquired resistanceEuropean Journal of Immunology, 1995
- Lack of Acidification in Mycobacterium Phagosomes Produced by Exclusion of the Vesicular Proton-ATPaseScience, 1994